三金片联合坦索罗辛及环丙沙星治疗慢性前列腺炎疗效观察

目的观察三金片联合坦索罗辛、环丙沙星治疗慢性前列腺炎的临床治疗效果。方法患者根据美国国立卫生研究院（NIH）制定的慢性前列腺炎分类标准选取Ⅱ型和ⅢA型慢性前列腺炎患者120例,并随机分为治疗组和对照组各60例联合治疗。治疗组服用三金片、坦索罗辛、环丙沙星;对照组仅服用坦索罗辛、环丙沙星;比较两组治疗1月前后的症状指数（NIH～CPSI）评分、前列腺液（EPS）白细胞计数及卵磷脂小体数量。结果治疗组总有效率为91．7％,对照组总有效率为78．2％,两组总有效率差异有统计学意义（P〈0．01）,两组发生不良反应均为轻度且持续时间较短。结论三金片联合坦索罗辛、环丙沙星治疗慢性前列腺炎的疗效满意,无明显不良反应,值得临床推广使用。     

舍尼通联合左氧氟沙星治疗慢性非细菌性前列腺炎

目的 观察舍尼通联合左氧氟沙星治疗慢性非细菌性前列腺炎的效果及安全性.方法 给67例慢性非细菌性前列腺炎患者口服舍尼通和左氧氟沙星(可乐必妥)1～3个月,比较治疗前和治疗4、8、12周后NJH-CPSI评分、症状评分、生活质量评分、疼痛症状评分、排尿症状评分以及EPS中WBC计数和pH值等指标的情况.结果 用药前与用药后4、8、12周各项指标相比,差异有统计学意义(P＜0.05或P＜0.01).治疗后4周与治疗后8、12周各项指标相比有统计学意义(P＜0.05).但治疗后8周与12周相比各项指标无统计学意义(P＞0.05).治疗后治疗总效率达到92.5%.结论 舍尼通联合左氧氟沙星治疗慢性非细菌性前列腺炎安全、有效.     

舍尼通和抗生素联合用药治疗慢性非细菌性前列腺炎临床研究

目的评价舍尼通(R)与抗生素联合用药治疗慢性非细菌性前列腺炎的有效性及耐受性.方法采用双盲、平行对照、多中心临床试验研究方法,通过Stamey试验、前列腺按摩液(EPS)常规及美国国立卫生院慢性前列腺炎症状评分(NIH-CPSI),筛选出160例慢性非细菌性前列腺炎患者,随机分为试验组(80例,脱落1例)和对照组(80例).试验组前4周合用舍尼通(R)和左氧氟沙星,后4周单用舍尼通(R),服用剂量为舍尼通2次/d,1片/次,左氧氟沙星2次/d,0.1g/次;对照组方法同上,仅将舍尼通(R)换为安慰剂.所有患者均行入组前、治疗第4周和第8周随访并行NIH-CPSI评分、EPS等检查及药物不良反应的评估.结果治疗后4周和8周,试验组疼痛评分降低分别为3.34±2.45,4.33±3.13,排尿评分降低分别为2.22±1.79,2.77±2.04;对照组疼痛评分降低分别为2.28±2.42,3.30±3.29,排尿评分降低分别为1.24±1.67,1.83±2.25.两组治疗前后的自身对比均差异有显著性(P＜0.01),生活质量影响评分差异也有显著性(P＜0.05).组间比较,试验组较对照组第4周和第8周疼痛和排尿评分差异均有显著性(P＜0.01或P＜0.05).两组治疗前后白细胞、卵磷脂小体差异无显著性(P＞0.05),对药物的耐受性差异无显著性(P＞0.05),无严重不良反应事件发生.结论舍尼通(R)与抗生素联合用药方案能更有效地缓解慢性非细菌性前列腺炎患者的疼痛不适症状和排尿症状,耐受性好,值得在临床上推广应用.     

舍尼通~和抗生素联合用药治疗慢性非细菌性前列腺炎临床研究

目的:评价舍尼通与抗生素联合用药治疗慢性非细菌性前列腺炎的有效性及耐受性。方法:采用双盲、平行对照、多中心临床试验研究方法,通过Stam ey试验、前列腺按摩液(EPS)常规及美国国立卫生院慢性前列腺炎症状评分(NIH-CPSI),筛选出160例慢性非细菌性前列腺炎患者,随机分为试验组(80例,脱落1例)和对照组(80例)。试验组前4周合用舍尼通和左氧氟沙星,后4周单用舍尼通,服用剂量为舍尼通2次/d,1片/次,左氧氟沙星2次/d,0.1 g/次;对照组方法同上,仅将舍尼通换为安慰剂。所有患者均行入组前、治疗第4周和第8周随访并行NIH-CPSI评分、EPS等检查及药物不良反应的评估。结果:治疗后4周和8周,试验组疼痛评分降低分别为3.34±2.45,4.33±3.13,排尿评分降低分别为2.22±1.79,2.77±2.04;对照组疼痛评分降低分别为2.28±2.42,3.30±3.29,排尿评分降低分别为1.24±1.67,1.83±2.25。两组治疗前后的自身对比均差异有显著性(P<0.01),生活质量影响评分差异也有显著性(P<0.05)。组间比较,试验组较对照组第4周和第8周疼痛和排尿评分差异均有显著性(P<0.01或P<0.05)。两组治疗前后白细胞、卵磷脂小体差异无显著性(P>0.05),对药物的耐受性差异无显著性(P>0.05),无严重不良反应事件发生。结论:舍尼通与抗生素联合用药方案能更有效地缓解慢性非细菌性前列腺炎患者的疼痛不适症状和排尿症状,耐受性好,值得在临床上推广应用。     

丹赤前列汤治疗慢性前列腺炎86例

目的:观察丹赤前列汤治疗慢性前列腺炎的临床疗效.方法:将172例患者,分为2组,治疗组服用丹赤前列汤,对照组服用前列泰片,观察两组治疗前后症候疗效及相关指标.结果:治疗组治疗显效率36.05%,总有效率为90.69%;对照组显效率30.02%,总有效率为80.23%.两组总有效率差异有显著性意义(P＜0.05).治疗前后前列腺液常规检查、及NIH-CPSI评分差异明显(P＜0.05).结论:丹赤前列汤治疗慢性前列腺炎有良好的疗效.     

罗非昔布联合抗生素治疗慢性前列腺炎

目的:探讨罗非昔布治疗慢性前列腺炎的有效性及安全性.方法:采用随机对照方法,对101例慢性前列腺炎患者应用罗非昔布加抗生素治疗(罗非昔布组)进行8～12周的临床观察,按照美国国家卫生研究院慢性前列腺炎症状评分(NIH CPSI)评估疗效:并与同法应用相同的抗生素对照组(124例)进行比较.结果:罗非昔布组NIH-CPSI总分、疼痛与不适症状评分及排尿症状评分平均降低均较对照组显著(均P＜0.05);罗非昔布组和治愈、显效、总有效率(95.05%)明显高于对照组(52.42%)(P＜0.05).治疗期间罗非昔布组共发生轻度药物不良反应5例(4.95%).结论:罗非昔布联合抗生素治疗慢性前列腺炎疗效显著,安全性好.     

前列消颗粒治疗慢性非细菌性前列腺炎30例

目的：观察前列消颗粒治疗慢性前列腺炎的疗效及其对尿道括约肌和盆底肌功能的影响。方法：选择60例慢性非细菌性前列腺炎患者,分为2组,治疗组30例口服前列消颗粒,对照组30例口服舍尼通片,共30d,观察治疗前后慢性前列腺症状评分（NIH—CPSI）、尿流率、盆底肌肌电图变化。结果：两组治疗后NIH—CPSI评分明显降低,平均尿流率、最大尿流率、盆底肌肌电图比值参数均明显提高,治疗组疗效明显优于对照组（P〈0．05）。结论：前列消颗粒能够明显改善慢性非细菌性前列腺炎临床症状,其松弛与缓解后尿道平滑肌及盆底肌痉挛可能是疗效机制之一。     

舍尼通治疗慢性非细菌性前列腺炎和前列腺痛的临床研究(附40例报告)

为探讨舍尼通治疗慢性非细菌性前列腺炎和前列腺癌的效果。我院自1997年7月～1997年11月应用舍厄通治疗40例慢性非细菌前列腺炎和前列腺痛,治疗疗程为4周。总有效率为72.5％,治愈率为32.5％,而且主、客观的临床指标均有显著性改善,并且无其它副作用。本临床研究结果表明舍尼通可作为治疗慢性前列腺炎的药物。     

前列腺注药、按摩联合吲哚美辛栓治疗慢性前列腺炎的随机对照研究

目的 探讨慢性前列腺炎(chronic Prostatitis,CP)的有效治疗方法.方法 600例慢性前列腺炎患者随机分成A、B、C三组,A组:前列腺注药按摩联合吲哚美辛栓200例:B组:抗生素200例;C组:抗生素联合普适泰(商品名:舍尼通)200例,三种方法 各治疗2个月,随访1～3年,对比治疗前后三种疗法的疗效...     

通淋汤治疗湿热下注型慢性前列腺炎的临床研究

目的:探讨通淋汤治疗湿热下注型慢性前列腺炎的临床疗效。方法:选取湿热下注型慢性前列腺炎患者50例,采用随机分组方法分为治疗组(通淋汤组)和对照组(左氧氟沙星胶囊组)各25例,治疗4周后对其疗效进行判断。结果:治疗组临床显效17例,有效7例,无效1例,总有效率96%;对照组临床显效7例,有效11例,无效7例,总有效率72%。两组在中医症状评分、疼痛、排尿症状等方面均有改善,NIH-CPSI评分方面与对照组相比有统计学差异(P0.05)。治疗组2例在服用中药时出现腹泻,中药减量后症状缓解;对照组1例出现胃肠道不适,减半剂量后症状缓解。临床随访1年,治疗组临床复发6例,复发率为24%,对照组临床复发12例,复发率为48%。结论:通淋汤治疗湿热下注型慢性前列腺炎有较好疗效,能改善患者的临床症状,有明显改善排尿症状作用,可减少临床复发率。     

Clinical effect of Cernilton in chronic prostatitis]

Twenty-five patients with chronic prostatitis were given Cernilton tablets. Improvement of subjective symptoms and objective findings was noted in 96.0% and 76.0% of the cases. Sonographic findings in the prostate showed 33-100% improvement in four objective items. No side effects were observed in any case after Cernilton medication. Cernilton was judged to be an effective drug for chronic prostatitis.     

A Japanese version of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI,Okayama version) and the clinical evaluation of cernitin pollen extract for chronic non-bacterial prostatitis

PURPOSE: The chronic prostatitis syndromes are common disorders in urologic practice and present various clinical symptoms. The development of a chronic prostatitis symptom index appropriate for judgment of therapeutic effects is awaited since the pathophysiology and appropriate treatment are not well defined so far. We developed a Japanese version of the National Institutes of Health Chronic Prostatitis Symptoms Index (NIH-CPSI, Okayama version), and examined its usefulness. In addition, we evaluated clinical effects of Cernilton for chronic nonbacterial prostatitis using this symptom index. SUBJECTS AND METHODS: A total of 87 patients including 34 patients with NIH chronic prostatitis category III, 35 patients with BPH and 18 patients for control group who visited the Department of Urology at Okayama University Medical School filled in the questionnaire of our Japanese version of the NIH-CPSI to compare the NIH-CPSI scores among three groups. Twenty-four patients with NIH chronic prostatitis category III (IIIa 16, IIIb 8) were treated with Cernilton and the NIH-CPSI scores were examined before and after its administration. RESULTS: The pain/discomfort domain score was 9.79 (mean) in the chronic prostatitis group, 1.66 in the BPH group and 0.39 in the control group; that of the urinary symptom domain was 3.82, 3.29 and 0.72, respectively; and that of the quality of life (QOL) was 8.21, 4.17 and 1.39, respectively. The pain/discomfort domain score was significantly higher in the chronic prostatitis group than in the other groups; the QOL domain score was higher in the order of the chronic prostatitis group, the BPH group and the control group. In the chronic prostatitis group, there was a significant, positive correlation between the pain/discomfort domain score and that of the QOL, and between the urinary symptom domain score and that of the QOL. These results suggested the usefulness of our Japanese version of the NIH-CPSI as a parameter of the severity of chronic prostatitis. Examination of changes in the NIH-CPSI scores revealed that scores of the items in all domains were significantly lower 4 to 6 weeks after the start of administration of Cernilton than those obtained before the drug administration in patients with chronic prostatitis. CONCLUSIONS: A Japanese version of NIH-CPSI (Okayama version) accurately reflects clinical symptoms and the QOL in patients with chronic prostatitis. It seemed to be a useful and appropriate system for scoring symptoms of chronic prostatitis, indicating further studies on translation, adaptation and validation of the NIH-CPSI in Japan.     

盐酸坦索罗辛缓释胶囊、普适泰联合高压氧等综合疗法对前列腺炎(ⅢB)患者的疗效

目的 观察综合疗法(盐酸坦索罗辛缓释胶囊、普适泰联合高压氧等措施)治疗前列腺炎(ⅢB)患者的临床疗效.方法 选取2014年4月至2015年2月期间本院收治的前列腺炎患者120例作为研究对象,所有患者均为ⅢB型.根据患者入院先后分为观察组和对照组各60例.对照组患者应用普适泰+盐酸坦索罗辛缓释胶囊,观察组在对照组基础上采取高压氧治疗,并指导盆底肌肉训练.结果 治疗过程中共有6例患者失访,其中观察组2例、对照组4例.经半年治疗观察组总有效率为93.10％ (54/58),对照组为76.79％(43/56),观察组明显高于对照组(P＜0.05).治疗3个月和6个月时观察组NIH-CPSI积分明显优于对照组(P＜0.05);观察组、对照组在治疗3个月、6个月时均优于入组时水平(P＜0.05).两组患者在治疗结束后,尿频、尿急、尿不尽、夜尿以及总评分均较治疗前明显改善(P＜0.05);治疗6个月时,观察组患者尿频、尿急、尿不尽、夜尿和总评分优于治疗3个月时,对照组总评分优于治疗3个月时(P＜0.05);观察组治疗3个月时尿不尽症状、治疗6个月时尿频、尿急、夜尿评分优于对照组(P＜0.05).结论 采用盐酸坦索罗辛缓释胶囊、普适泰、高压氧等一系列综合疗法治疗ⅢB型前列腺炎患者疗效显著,患者排尿异常得到良好改善,值得进一步研究和应用.     

炎列平冲剂对慢性非细菌性前列腺炎实验小鼠的影响观察

目的 :通过实验研究 ,探讨炎列平冲剂对慢性非细菌性前列腺炎病人症状和尿流率影响的机理。　方法 :将 32只C5 7BL/ 6小鼠分成炎列平组 (10只 )、舍尼通组 (10只 )、模型对照组 (6只 )和正常对照组 (6只 ) ,采用免疫佐剂法造模后 ,分别予炎列平 (0 .84g/只 )、舍尼通 (7.5mg/只 )和蒸馏水 (0 .5ml)灌胃 1个月 ,观察各组小鼠的前列腺湿重、病理改变、血清TNF α、IL 2含量。　结果 :与对照组相比 ,炎列平组和舍尼通组的前列腺湿重明显降低(P <0 .0 5 ) ;慢性炎症的病理表现明显好转 ,以炎列平组更显著 ;炎列平组和舍尼通组IL 2明显降低 ;炎列平组TNF α显著增高 (P <0 .0 5 )。　结论 :炎列平冲剂治疗慢性非细菌性前列腺炎的机理可能在于缓解尿道平滑肌痉挛、抗炎、调节免疫功能和改善局部血液循环。     

Treatment of chronic prostatitis and prostatodynia with pollen extract

Chronic abacterial prostatitis and prostatodynia are notoriously difficult both to diagnose and to treat. These patients tend to have received several courses of antibiotics, antiinflammatory agents or adrenergic blockade and various other therapeutic manoeuvres with little success. The pollen extract, Cernilton, is reported to be effective in the treatment of this condition and we present the results of an open trial with Cernilton in a group of 15 patients with chronic prostatitis and prostatodynia. In 13 patients there was either complete and lasting relief of symptoms or a marked improvement; 2 patients failed to respond. Cernilton was found to be effective in the treatment of chronic prostatitis and prostatodynia. Its precise mode of action is not known, although experimental studies suggest that it has anti-inflammatory and anti-androgenic properties.     

A long-term therapeutic experience with Cernilton in chronic prostatitis

Thirty-two patients with chronic prostatitis were given 6 tables of Cernilton daily for 12.6 weeks on the average. Improvement of subjective symptoms and objective findings was noted in 74.2% and 65.6% of the cases, respectively. The effective rate was 75.0%. No subjective symptoms or abnormal changes in laboratory data were observed in any case after Cernilton medication.     

前列腺灌注管加压灌注药物治疗慢性前列腺炎

目的：观察应用前列腺灌注管加压灌注药物治疗慢性前列腺炎的效果。方法：对１７６例慢性前列腺炎患者经尿道置入前列腺灌注管加压灌注药物并联合多功能前列腺治疗仪治疗。结果：１７６便中治愈１３４例,好转３２例,有效率９４．３％。治疗后随访６￣１８个月,８例复发。结论：应用前列腺灌中压灌注药物并联合多功能前列腺治疗仪治疗慢性前列腺炎具有疗效好,副作用少的优点,是治疗慢性前列腺炎可供选择的有效方法之一。     

Clinical studies against chronic prostatitis and prostatitis-like syndrome (2). Evaluation of therapeutic effect

We treated 229 cases of chronic prostatitis (bacterial in 29, non-bacterial in 200) and 238 cases of prostatitis-like syndrome and evaluated the clinical efficacy. Clinical efficacy was seen in 77.3% of the chronic prostatitis cases (82.8% bacterial, 76.5% non-bacterial) and 53.8% of the prostatitis-like syndrome cases, with a statistical difference between these two types of disease (p less than 0.01). Treatment included chemotherapy, anti-inflammation agents and minor tranquilizers. None of them were effective against the prostatitis-like syndrome. On the other hand, combination usage (chemotherapies and anti-inflammation agent) was satisfactory on chronic bacterial prostatitis. Also on chronic non-bacterial prostatitis, chemotherapy was significantly effective (p less than 0.05%). Chemotherapeutic effectiveness against chronic prostatitis (both bacterial and non-bacterial) was high with sulfamethoxazole-trimethoprim, tetracyclines, cephalosporins, nalidixic acid and penicillins in this order. There was no difference among these drugs. Prostatic massage was generally effective especially for chronic non-bacterial prostatitis (p less than 0.05) and prostatitis-like syndrome (p less than 0.01). Light psychological treatment was significantly effective toward some cases of prostatitis-like syndrome with strong psychosomatic factors (p less than 0.01).     

Clinical studies with antimicrobic agent "Dolcol" for chronic prostatitis

Chronic prostatitis is possibly the most common infectious disease in middle-aged men. Clinical investigation was made on 24 outpatients with chronic prostatitis at our department, during the period of October, 1983 to August, 1984. The diagnostic criterion of the prostatitis was detection of more than ten leukocytes per high power field on microscopic examination of the expressed prostatic secretion and urine after prostatic massage. Twenty-four patients with chronic prostatitis were treated with 2 tablets of Dolcol (Pipemidic acid, PPA) three times daily for 7-30 days. The effectiveness was evaluated by improvement of subjective symptoms and objective findings. The results of the therapy with PPA on chronic prostatitis were excellent in 8 patients (33.3%), good in 10 (41.7%), fair in 2 (8.3%), and poor in 4 (16.7%). The effective rate was 83.3%, while no side effects were noted. Therefore, PPA was suggested to be effective against chronic prostatitis.     

慢性前列腺炎患者伴随的情绪障碍及治疗

目的：探讨慢性前列腺炎（CP）患者焦虑、抑郁等情绪障碍的解决方法。方法：将90例伴有抑郁症状的CP患者随机分为3组,其中30例采用骶管注药治疗（骶管注药组）,30例服用曲唑酮治疗（曲唑酮组）,30例给骶管注药加曲唑酮联合治疗（联合组）。结果：骶管注药组、曲唑酮组及联合组CP治愈率分别为70％、17％和87％,抑郁症状缓解率为21％、42％和77％。结论：对伴有焦虑抑郁症状的CP患者在治疗CP的同时应给予有效的抗抑郁治疗。